Clinical Trial Detail

NCT ID NCT02492711
Title Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors MacroGenics
Indications

Her2-receptor positive breast cancer

Therapies

Vinorelbine

Capecitabine

Gemcitabine

Trastuzumab

Eribulin

MGAH22

Age Groups: adult

Additional content available in CKB BOOST